Does the media refer more to LFCR or SPRO?

In the previous week, Spero Therapeutics had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Spero Therapeutics and 3 mentions for Lifecore Biomedical. Spero Therapeutics' average media sentiment score of 0.43 beat Lifecore Biomedical's score of -0.22 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VNDA or SPRO?

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Spero Therapeutics. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 6 mentions for Spero Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Spero Therapeutics' score of 0.43 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SIGA or SPRO?

Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Spero Therapeutics 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable valuation & earnings, SIGA or SPRO?

Siga Technologies has higher earnings, but lower revenue than Spero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $52.36M 4.31 $23.28M N/A N/A Spero Therapeutics $66.80M 0.89 $8.57M $0.11 9.27

Does the media prefer SIGA or SPRO?

In the previous week, Siga Technologies had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Siga Technologies and 6 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.43 beat Siga Technologies' score of -0.03 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Siga Technologies 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GLAS or SPRO?

In the previous week, Spero Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 6 mentions for Spero Therapeutics and 5 mentions for Glass House Brands. Spero Therapeutics' average media sentiment score of 0.43 beat Glass House Brands' score of -0.33 indicating that Spero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SPRO or PALI?

In the previous week, Palisade Bio had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Palisade Bio and 6 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.43 beat Palisade Bio's score of -0.24 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Palisade Bio 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Spero Therapeutics (SPRO) Competitors

$1.00 -0.02 (-1.96%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 -0.02 (-1.80%)

As of 07:30 PM Eastern

Compare

SPRO vs. LFCR, VNDA, SIGA, GLAS, and PALI

Should you buy Spero Therapeutics stock or one of its competitors? Spero Therapeutics's main competitors and comparable companies include Lifecore Biomedical (LFCR), Vanda Pharmaceuticals (VNDA), Siga Technologies (SIGA), Glass House Brands (GLAS), and Palisade Bio (PALI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Spero Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Lifecore Biomedical currently has a consensus target price of $6.50, suggesting a potential upside of 1.56%. Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Spero Therapeutics has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.88	-$70.51M	-$1.86	N/A
Spero Therapeutics	$66.80M	0.89	$8.57M	$0.11	9.27

In the previous week, Spero Therapeutics had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 6 mentions for Spero Therapeutics and 3 mentions for Lifecore Biomedical. Spero Therapeutics' average media sentiment score of 0.43 beat Lifecore Biomedical's score of -0.22 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Lifecore Biomedical's net margin of -56.80%. Spero Therapeutics' return on equity of 16.17% beat Lifecore Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-56.80%	N/A	-29.53%
Spero Therapeutics	24.90%	16.17%	12.57%

Lifecore Biomedical has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Summary

Spero Therapeutics beats Lifecore Biomedical on 12 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Spero Therapeutics has lower revenue, but higher earnings than Vanda Pharmaceuticals. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.16	-$220.47M	-$4.62	N/A
Spero Therapeutics	$66.80M	0.89	$8.57M	$0.11	9.27

In the previous week, Vanda Pharmaceuticals had 5 more articles in the media than Spero Therapeutics. MarketBeat recorded 11 mentions for Vanda Pharmaceuticals and 6 mentions for Spero Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.73 beat Spero Therapeutics' score of 0.43 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vanda Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

Spero Therapeutics has a net margin of 24.90% compared to Vanda Pharmaceuticals' net margin of -119.87%. Spero Therapeutics' return on equity of 16.17% beat Vanda Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-119.87%	-62.70%	-37.53%
Spero Therapeutics	24.90%	16.17%	12.57%

88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vanda Pharmaceuticals currently has a consensus target price of $13.50, suggesting a potential upside of 225.30%. Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Given Spero Therapeutics' higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Vanda Pharmaceuticals and Spero Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Spero Therapeutics compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Spero Therapeutics has a net margin of 24.90% compared to Siga Technologies' net margin of 1.31%. Spero Therapeutics' return on equity of 16.17% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	1.31%	0.40%	0.35%
Spero Therapeutics	24.90%	16.17%	12.57%

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Siga Technologies has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

Siga Technologies has higher earnings, but lower revenue than Spero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$52.36M	4.31	$23.28M	N/A	N/A
Spero Therapeutics	$66.80M	0.89	$8.57M	$0.11	9.27

In the previous week, Siga Technologies had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Siga Technologies and 6 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.43 beat Siga Technologies' score of -0.03 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Siga Technologies	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Given Spero Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spero Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Spero Therapeutics beats Siga Technologies on 11 of the 15 factors compared between the two stocks.

How does Spero Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Spero Therapeutics has a net margin of 24.90% compared to Glass House Brands' net margin of -31.68%. Spero Therapeutics' return on equity of 16.17% beat Glass House Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	-31.68%	-60.92%	-15.69%
Spero Therapeutics	24.90%	16.17%	12.57%

25.6% of Spero Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Glass House Brands currently has a consensus price target of $11.00, suggesting a potential upside of 480.47%. Spero Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 488.24%. Given Spero Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Spero Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Spero Therapeutics has lower revenue, but higher earnings than Glass House Brands. Glass House Brands is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$181.98M	0.97	-$29.66M	-$0.76	N/A
Spero Therapeutics	$66.80M	0.89	$8.57M	$0.11	9.27

In the previous week, Spero Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 6 mentions for Spero Therapeutics and 5 mentions for Glass House Brands. Spero Therapeutics' average media sentiment score of 0.43 beat Glass House Brands' score of -0.33 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Spero Therapeutics beats Glass House Brands on 12 of the 14 factors compared between the two stocks.

How does Spero Therapeutics compare to Palisade Bio?

Spero Therapeutics (NASDAQ:SPRO) and Palisade Bio (NASDAQ:PALI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

In the previous week, Palisade Bio had 2 more articles in the media than Spero Therapeutics. MarketBeat recorded 8 mentions for Palisade Bio and 6 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.43 beat Palisade Bio's score of -0.24 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Palisade Bio	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 488.24%. Palisade Bio has a consensus target price of $9.00, suggesting a potential upside of 669.23%. Given Palisade Bio's stronger consensus rating and higher possible upside, analysts clearly believe Palisade Bio is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Spero Therapeutics has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	0.89	$8.57M	$0.11	9.27
Palisade Bio	$250K	815.58	-$16.78M	-$0.48	N/A

25.6% of Spero Therapeutics shares are owned by institutional investors. Comparatively, 11.8% of Palisade Bio shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Palisade Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Spero Therapeutics has a net margin of 24.90% compared to Palisade Bio's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat Palisade Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
Palisade Bio	N/A	-34.63%	-33.19%

Spero Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Palisade Bio has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Summary

Spero Therapeutics beats Palisade Bio on 10 of the 17 factors compared between the two stocks.

Get Spero Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRO vs. The Competition

Export

Metric	Spero Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.40M	$13.78B	$7.90B	$12.24B
Dividend Yield	N/A	2.56%	2.46%	4.51%
P/E Ratio	9.27	25.69	34.50	28.17
Price / Sales	0.87	7.72	8.90	6.00
Price / Cash	6.70	15.79	22.23	22.80
Price / Book	0.95	5.24	4.50	3.83
Net Income	$8.57M	$2.87B	$3.51B	$390.69M
7 Day Performance	-1.96%	1.82%	0.42%	1.60%
1 Month Performance	-15.25%	-5.30%	-5.01%	-6.85%
1 Year Performance	-62.41%	-7.27%	-0.84%	-7.22%

Spero Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRO Spero Therapeutics	4.634 of 5 stars	$1.00 -2.0%	$6.00 +500.0%	-61.1%	$59.40M	$66.80M	9.27	25	Earnings Report Analyst Upgrade
LFCR Lifecore Biomedical	1.4816 of 5 stars	$6.42 +0.4%	$6.50 +1.3%	-17.3%	$242.83M	$128.87M	N/A	382	News Coverage
VNDA Vanda Pharmaceuticals	4.2109 of 5 stars	$3.72 -4.0%	$13.50 +262.6%	-5.3%	$225.25M	$229.28M	N/A	533
SIGA Siga Technologies	0.1677 of 5 stars	$3.11 +5.3%	N/A	-50.1%	$223.09M	$53.66M	N/A	49	Earnings Report
GLAS Glass House Brands	2.4683 of 5 stars	$2.37 +0.2%	$11.00 +365.1%	N/A	$219.35M	$181.98M	N/A	357	News Coverage Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRO) was last updated on 11/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spero Therapeutics (SPRO) Competitors

SPRO vs. LFCR, VNDA, SIGA, GLAS, and PALI

How does Spero Therapeutics compare to Lifecore Biomedical?

Summary

How does Spero Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Spero Therapeutics compare to Siga Technologies?

Summary

How does Spero Therapeutics compare to Glass House Brands?

Summary

How does Spero Therapeutics compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spero Therapeutics (SPRO) Competitors

SPRO vs. LFCR, VNDA, SIGA, GLAS, and PALI

How does Spero Therapeutics compare to Lifecore Biomedical?

Do analysts recommend LFCR or SPRO?

Which has better earnings and valuation, LFCR or SPRO?

Does the media refer more to LFCR or SPRO?

Do insiders & institutionals have more ownership in LFCR or SPRO?

Is LFCR or SPRO more profitable?

Which has more volatility and risk, LFCR or SPRO?

Summary

How does Spero Therapeutics compare to Vanda Pharmaceuticals?

Which has better earnings and valuation, VNDA or SPRO?

Does the media refer more to VNDA or SPRO?

Which has more volatility and risk, VNDA or SPRO?

Is VNDA or SPRO more profitable?

Do insiders & institutionals have more ownership in VNDA or SPRO?

Do analysts recommend VNDA or SPRO?

Summary

How does Spero Therapeutics compare to Siga Technologies?

Is SIGA or SPRO more profitable?

Do institutionals & insiders have more ownership in SIGA or SPRO?

Which has more risk and volatility, SIGA or SPRO?

Which has preferable valuation & earnings, SIGA or SPRO?

Does the media prefer SIGA or SPRO?

Do analysts prefer SIGA or SPRO?

Summary

How does Spero Therapeutics compare to Glass House Brands?

Is GLAS or SPRO more profitable?

Do insiders & institutionals have more ownership in GLAS or SPRO?

Do analysts prefer GLAS or SPRO?

Which has stronger earnings and valuation, GLAS or SPRO?

Does the media refer more to GLAS or SPRO?

Summary

How does Spero Therapeutics compare to Palisade Bio?

Does the media favor SPRO or PALI?

Do analysts prefer SPRO or PALI?

Which has preferable earnings & valuation, SPRO or PALI?

Do insiders and institutionals hold more shares of SPRO or PALI?

Is SPRO or PALI more profitable?

Which has more volatility & risk, SPRO or PALI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRO vs. The Competition

Spero Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools